ARAlexandra Ritenour

Alexandra Ritenour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Ritenour has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Streamlining Hepatitis C Treatment: Implementation of a Clinical Pharmacist‐Driven Medication Management Program

    by Alexandra Ritenour, Kiersi Harmon

    Background: Hepatitis C virus (HCV) affects over 3.9 million individuals in the United States and is effectively treated with direct‐acting antiviral (DAA) agents. Clinical pharmacists (CPs) may be the ideal provider to bridge gaps in HCV care by selecting appropriate therapy following drug–drug interaction (DDI) review, navigating access barriers, and supporting adherence. Although CP involvement in HCV care has demonstrated clinical value, there is limited literature describing CP workflows, patient interventions, and CP‐led programs that support patients from treatment initiation through sustained virologic response at 12 weeks (SVR12). This study aims to quantify and categorize CP‐driven enrollments in a Hepatitis C Clinical Program (HCCP) and assess its impact on patient safety, operational, and clinical outcomes. Methods: This retrospective descriptive study evaluates a CP‐driven HCCP within a health system specialty pharmacy (HSSP) from May 6, 2024 to March 6, 2025. Patients with a referral to the CP for HCV treatment selection, or external patients with a DAA claim at the HSSP, were eligible for enrollment in the program. The HCCP consisted of six points of clinical care: CP therapy selection, medication access and order placement, prescription triage and patient education, follow‐up throughout treatment, intervention support, and laboratory monitoring through SVR12. Results: A total of 122 patients were enrolled in the HCCP. Most patients were treatment‐naïve (90%) and non‐cirrhotic (79%). DDIs were identified in 57% of patients, with statin therapy being the most common (46%). Time‐to‐treatment was 4 days or less for 76% of patients, with an 88% HSSP prescription capture rate. A 97% SVR12 rate was achieved, and 92% of patients completed therapy on time. Conclusion: This study highlights the role of the CP in HCV care and their impact on patient safety and clinical and operational outcomes. Results support further development of CP‐driven practice changes and support the implementation of a similar program within other HSSPs.

  • Pharmacist-led steroid stewardship in inflammatory diseases: evaluating glucocorticoid use and patient outcomes

    by Vanessa Lopez, Alexandra Ritenour, Kiersi Harmon

    Purpose: Glucocorticoids (GCs) are widely used in inflammatory diseases but are associated with significant adverse effects when used long term. Specialty pharmacists are uniquely positioned to monitor and optimize GC use through longitudinal patient management. This study aimed to characterize GC utilization and identify opportunities for pharmacist-led stewardship within a health-system specialty pharmacy. Methods: This prospective, multi-center descriptive study implemented a pharmacist-driven GC questionnaire within CHRISTUS Specialty Pharmacy workflow. The questionnaire was incorporated into initial, and follow-up clinical assessments conducted every four to ten months. Eligible patients included those with inflammatory conditions receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Data collected between October 1, 2025, and January 15, 2026, were analyzed using descriptive statistics. Results: Among 688 patients, 17.4% reported active GC use. Mean duration of GC therapy was 112 days and was longer in patients receiving biologic DMARDs (184 days) compared to targeted synthetic DMARDs (105 days). GC use was most common in lupus (54.6%), rheumatoid arthritis (25.8%), and ulcerative colitis (25.5%). The majority of GC users had uncontrolled disease (63.9%), while minimal adverse effects were reported. Conclusion: Glucocorticoid use remains prevalent among patients receiving specialty therapies, particularly in those with uncontrolled disease. These findings highlight opportunities for pharmacist-led interventions focused on GC deprescribing, monitoring, and optimization of long-term outcomes.

  • Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

    by Anthony Yu, Alexandra Ritenour, Jennifer Vincent, Chanhyun Park, Karen Rascati, Paul Godley

    To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis. This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis. A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis. This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.

  • Impact of specialty pharmacy collaboration with rheumatology clinics to improve the achievement of treat-to-target goals in patients with rheumatoid arthritis: a pilot study

    by Alexandra Ritenour, Anthony Yu, Diana Li, Tonya Martin

    In rheumatoid arthritis, the use of Routine Assessment of Patient Index Data 3 (RAPID3) assessments to meet treat-to-target goals is endorsed by the 2021 American College of Rheumatology guidelines. In November 2020, the Baylor Scott & White specialty pharmacy implemented a new service that included more frequent collection of RAPID3 scores and standardized provider communication for patients co-managed by a Baylor Scott & White rheumatology clinic. The objective was to evaluate the impact of this new service on rheumatoid arthritis disease activity. Before the new service started, patients followed a protocol of RAPID3 assessments that occurred every 6 months; once the service began, patients were followed using an algorithm in which patients with higher disease activity were contacted more frequently. Eighty-six percent of patients in the pre-intervention group (n = 7) compared with 100% of patients in the post-intervention group (n = 10) had high to moderate disease activity at baseline. Within a 6-month follow-up period in both groups, the percentage of high to moderate disease activity patients decreased by 30% in the post-intervention group and remained the same in the pre-intervention group. These results support the positive impact increased specialty pharmacy services may have on clinical outcomes; therefore, the continued expansion of these services should be considered.